Innovus Pharmaceuticals (OTCMKTS:INNVD) issued its quarterly earnings data on Monday, April 1st. The company reported ($0.99) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.11) by $0.12, Morningstar.com reports. The firm had revenue of $4.75 million for the quarter, compared to analysts’ expectations of $8.13 million. Innovus Pharmaceuticals had a negative net margin of 34.51% and a negative return on equity of 682.54%.
OTCMKTS INNVD traded down $0.16 during trading hours on Wednesday, hitting $3.59. The company’s stock had a trading volume of 4,005 shares, compared to its average volume of 17,924. Innovus Pharmaceuticals has a twelve month low of $1.50 and a twelve month high of $19.37. The firm has a market capitalization of $8.47 million, a P/E ratio of -0.86 and a beta of 2.89.
Separately, ValuEngine cut shares of Innovus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 1st.
Innovus Pharmaceuticals Company Profile
Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.